Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-α antagonists

Journal of Rheumatology

Volumn 35, Issue 9, 2008, Pages 1745-1753

  Vera Llonch, Montserrat ^a   Massarotti, Elena ^b   Wolfe, Frederick ^c   Shadick, Nancy ^b   Westhovens, Rene ^d   Sofrygin, Oleg ^a   Maclean, Ross ^e   Li, Tracy ^e   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Abatacept; Cost effectiveness; Outcomes; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ABATACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SIMULATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY OF LIFE; QUESTIONNAIRES; RHEUMATOLOGY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 54049128977     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Scott DL. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704-12.
2. Fleischmann RM. Examining the efficacy of biologic therapy: Are there real differences? J Rheumatol 2002;29 Suppl 65:27-32.
3. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl II:ii13-ii16.
4. Finckh A, Simard JF, Gabay C, Guerne PA, for the SCQM physicians. Evidence for differential acquired drug resistance to anti-TNF agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:146-52.
5. Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: Subsequent outcome of initial responders. Rheumatology Oxford 2007;46:1153-6.
6. Duclos M, Gossec L, Ruyssen-Witrand A, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006;33:2433-9.
7. Geborek P, Crnkic M, Peterson IF, Saxne T. Etanercept, infliximab and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-7.
8. Flendrie M, Creemers MCW, Welsing PMJ, et al. Survival during treatment with tumor necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl II:30-3.
9. Ostergaard N, Unkershow J, Krog NS, et al. Poor remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept - Results from the nationwide Danish "DANBIO" database [abstract]. Ann Rheum Dis 2005;64 Suppl III:59.
10. Kristensen L, Geborek P, Saxne T. Adherence to therapy of etanercept and infliximab during first anti-TNF treatment course in rheumatoid arthritis [abstract]. Ann Rheum Dis 2005;64 Suppl III:431.
11. Pincus T, Yazici Y, van Vollenhoeven R. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for long term observations in standard care to complement clinical trials. J Rheumatol 2006;33:2372-5.
12. Van Vollenhoeven R. Switching between biological agents. Clin Exp Rheumatol 2004;22 Suppl 35:S115-S121.
13. Van Vollenhoeven R, Cullinane C, Bratt J, Klareskog L. Secondary loss of efficacy with TNF alpha antagonists [abstract]. Arthritis Rheum 2005;52 Suppl:S136.
14. Bennett AN, Peterson P, Zain A, et al. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology Oxford 2005;44:1026-31.
15. Sanmarti R, Gomez-Puerta JA, Rodriguez-Cros JR, et al. Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab [Spanish]. Med Clin Barc 2004;1229:321-4.
16. Hansen KE, Hildebrand JP, Genovese M, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-102.
17. Van Vollenhoeven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: Data from the STURE registry showing that switching tumor necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
18. Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003;30:2315-8.
19. Brocq O, Plubel Y, Breuil V, et al. Etanercept-infliximab switch in rheumatoid arthritis in 14 out of 131 patients treated with anti-TNF-alpha [French]. Presse Med 2002;31:1836-9.
20. Shergy WJ, Phillips RM Jr, Hunt RE, Hernandez J. Safety and efficacy of infliximab therapy after etanercept failure: A case series [abstract]. Arthritis Rheum 2001;44 Suppl:S81.
21. Cohen JD, Zaltni S, Morel J, et al. Switch anti-TNF alpha: a propos de 32 patients atteints de polyarthrite rhumatoide [abstract]. Rev Rheum 2002;70:996-7.
22. Boers M. Abatacept in rheumatoid arthritis: A new branch on the "biologics" tree. Ann Intern Med 2006;144:933-5.
23. Nogid A, Pham DQ. Role of abatacept in the management of rheumatoid arthritis. Clin Ther 2006;28:1764-77.
24. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatology Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
25. Genovese M, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
26. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: The Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
27. Brennan A, Bansback N, Reynolds A, Conway P. Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology Oxford 2003;42:1-13.
28. Clark W, Jobanputra P, Barton P, Burls A. Technology assessment report commissioned by the HTA programme on behalf of the National Institute for Clinical Excellence: The clinical and cost effectiveness of anakinra for the treatment of rheumatoid arthritis in adults. West Midlands Health Technology Assessment Collaboration (WMHTAC). 2003. [Internet. Accessed May 29, 2008.] Available from: http://www.nice.org.uk/nicemedia/pdf/Anakinra_assessmentreport. pdf
29. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-110.
30. Kobelt G, Johnsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology Oxford 2003;42:326-35.
31. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;64:1174-9.
32. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
33. Craig B, Black M, Sendi P. Uncertainty in decision models analyzing cost-effectiveness [letter]. Med Decis Making 2000;20:135-7.
34. Halpern E, Weinstein M, Hunink M, Gazelle GS. Representing first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 2000;20:314-22.
35. Kuntz K, Weinstein M. Modeling in economic evaluation. In: Drummond M, McGuire A, editors. Economic evaluation in health care: Merging theory with practice. New York: Oxford University Press; 2001:141-71.
36. Goldie S. Public health policy and cost-effectiveness analysis. Ch 15. J Ntl Cancer Inst Monograph 2003;31:102-10.
37. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
38. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, for the Panel on Cost-Effectiveness in Health and Medicine. Consensus Statement. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1253-58.
39. Lipsky PE, van der Heijde DMFM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
40. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
41. Olsen NJ, Stein MC. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
42. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: Evolving concepts. Arthritis Rheum 2001;44:1234-6.
43. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patient with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42.
44. Yelin E, Trupin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002;29:1851-7.
45. Sokka T, Hakkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the Health Assessment Questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 2004;63:494-7.
46. US Bureau of the Census. Statistical Abstract of the United States: Washington, DC, 2004.
47. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
48. Orencia® product label information (2006). Bristol Myers Squibb.
49. US Department of Human Services (DHHS), National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988-1994, NHANES III Adult, Exam and Laboratory Data files (CD ROM); Hyattsville, MD: Centers for Disease Control and Prevention;1996. Public Use Data File Documentation 762000. Available from the National Technical Information Service (NTIS), Springfield, VA.
50. Drug Topics® Red Book®. Montvale, NJ: Medical Economics Inc., 2006.
51. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46.
52. American Medical Association. Medicare RBRVS: The physician guide. Chicago, IL: American Medical Association; 2006.
53. US Bureau of Labor Statistics. Consumer Price Index. Washington, DC: US Department of Labor; 2006.
54. Feller W. An introduction to probability theory and its applications. Vol. 1. 3rd ed. New York: John Wiley & Sons; 1968.
55. Vera-Llonch M, Massarotti E, Shadick NA, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate [abstract]. Ann Rheum Dis 2007;66 Suppl II:277.
56. Rituximab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 126. 2007. [Internet. Accessed May 29, 2008). Available from: http://www.nice.org.uk/nicemedia/pdf/word/TA126guidance.doc
57. Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2002;47:655-61.
58. Wolfe F, Michaud K. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: Randomized controlled trials overestimate treatment response and effectiveness. Rheumatology Oxford 2005;44 Suppl 4:iv18-iv22.